Androgen deprivation therapy for prostate cancer: adverse effects and their management
Arai, G.; Okada, H.
Nihon Rinsho. Japanese Journal of Clinical Medicine 74(Suppl 3): 605-609
2016
ISSN/ISBN: 0047-1852 PMID: 27344802 Document Number: 687173
Document emailed within 1 workday
Related Documents
Koivisto, P.; Kononen, J.; Palmberg, C.; Tammela, T.; Hyytinen, E.; Isola, J.; Trapman, J.; Cleutjens, K.; Noordzij, A.; Visakorpi, T.; Kallioniemi, O.P. 1997: Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer Cancer Research 57(2): 314-319Buyyounouski, M.K. 2010: Androgen deprivation therapy in high-risk prostate cancer Oncology 24(9): 806; 809
Ying, J.; Yao, D.-H.; Ren, X.-M. 2003: Study of sexual hormone changes in prostate cancer patients before and after androgen deprivation therapy Zhonghua Nan Ke Xue 9(3): 191-192; 196
Alvarez Rodríguez, S.; Alonso Gordoa, T.; Burgos Revilla, F.Javier. 2018: Current status of androgen deprivation therapy in hormone-sensitive prostate cancer Archivos Espanoles de Urologia 71(3): 247-257
2015: (P063) Can Some High-Risk Prostate Cancer Patients Be Treated With a Shorter Course of Androgen Deprivation Therapy (ADT)? Oncology 29(4 Suppl. 1)
Ziaran, S.; Goncalves, F.M.; Wendl, J.; Trebaticky, B.; Breza, J.S. 2009: Evaluation of bone mass density on patients with prostate cancer prior to the start of androgen deprivation therapy Bratislavske Lekarske Listy 110(9): 559-562
Pickles, T.; Pollack, A. 2006: The case for dose escalation versus adjuvant androgen deprivation therapy for intermediate risk prostate cancer Canadian Journal of Urology 13(Suppl 2): 68-71
Rentsch, C.A.; Aebersold, D.M.; Merz, V.; Studer, U.E. 2005: Cancer of the prostate: importance of androgen deprivation and radiotherapy Revue Medicale Suisse 1(19): 1303-1306
Beuzeboc, P.; Richaud, P. 2003: Androgen replacement therapy and prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(5 Suppl 2: 1276-1277
Roux, C. 2003: Osteoporosis due to androgen suppression therapy in men with prostate cancer Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 13(2 Suppl 1: 24-27
Blank, K.R.; Whittington, R.; Arjomandy, B.; Wein, A.J.; Broderick, G.; Staley, J.; Malkowicz, S.B. 1999: Neoadjuvant androgen deprivation prior to transperineal prostate brachytherapy: smaller volumes, less morbidity Cancer Journal From Scientific American 5(6): 370-373
Pettaway, C.A. 1999: Racial differences in the androgen/androgen receptor pathway in prostate cancer Journal of the National Medical Association 91(12): 653-660
Hu, Y.-H.; Guo, J.-C.; Zhang, M. 2017: Bipolar androgen therapy: a novel therapeutic strategy for castration-resistant prostate cancer Zhonghua Nan Ke Xue 23(12): 1138-1140
Izbicka, E.; MacDonald, J.R.; Davidson, K.; Lawrence, R.A.; Gomez, L.; Von Hoff, D.D. 1999: 5,6 Dihydro-5'-azacytidine (DHAC) restores androgen responsiveness in androgen-insensitive prostate cancer cells Anticancer Research 19(2a): 1285-1291
Bastos, D.A.; Dzik, C.; Rathkopf, D.; Scher, H.I. 2014: Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer Oncology 28(8): 693-699
Xu, K.; Wang, X.; Ling, M.; Wong, Y. 2003: Growth inhibiting effects of terazosin on androgen-independent prostate cancer cell lines Chinese Medical Journal 116(11): 1673-1677
Amler, L.C.; Agus, D.B.; LeDuc, C.; Sapinoso, M.L.; Fox, W.D.; Kern, S.; Lee, D.; Wang, V.; Leysens, M.; Higgins, B.; Martin, J.; Gerald, W.; Dracopoli, N.; Cordon-Cardo, C.; Scher, H.I.; Hampton, G.M. 2000: Dysregulated expression of androgen-responsive and nonresponsive genes in the androgen-independent prostate cancer xenograft model CWR22-R1 Cancer Research 60(21): 6134-6141
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Neri, B.; Bartalucci, S.; Pieri, A.; Gemelli, M.T.; Rizzo, M.; Bartoletti, R.; Trippitelli, A.; Paoletti, M.C. 1989: Complete androgen blockade as treatment for advanced prostate cancer: clinical response and side-effects Anticancer Research 9(1): 13-16
Rees, J. 2015: Androgen deprivation therapy and cardiovascular risk Practitioner 259(1785): 5